Gilead said on Monday it will acquire Myogen Inc. for $2.5 billion, gaining control of Myogen's experimental heart medicines.
Gilead, the world's No. 3 biotech company by market value and a maker of several HIV drugs, will pay $52.50 per share for Myogen, representing a 50 percent premium over Friday's closing price of $35.08.
More from Reuters.
No comments:
Post a Comment